The objective of this study are to evaluate the safety and tolerability of ABT-199
(venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary
objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced
This is a single arm, open-label, non-randomized study with venetoclax (ABT-199) in CTCL
patients (subtypes mycosis fungoides and Szary syndrome only, and excluding transformed
mycosis fungoides). This study is planned to be conducted in 18 patients, 18 years or older
in age, undergoing a 5-week dose escalation protocol (per the US FDA package insert
guidelines of venetoclax for CLL). Safety monitoring will continue throughout the whole
period of drug administration and the treatment will be discontinued if intolerable toxicity
(defined in Stopping Rules) or disease progression occurs during this period.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.